Erik Knudsen
Chairperson/Associate Director of Basic Science
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (42)
Year:
2026
PURPOSE In both the early and advanced settings, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for use in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HER2–) breast cancer (BC) in combination with endocrine therapy and increase the duration of invasive disease-free survival and progression-free survival (PFS). The duration of response to these treatments is variable between individual patients, supporting the use of biomarkers to inform treatment. Here, we investigated plasma thymidine kinase activity (TKa) as a continuous prognostic and predictive biomarker of response to CDK4/6 inhibitor–based therapy in early and advanced hormone receptor–positive/HER2– BC. MATERIALS AND METHODS TKa levels were assessed longitudinally at baseline, on treatment, and post-treatment on plasma samples from 80 metastatic and 28 high-risk patients receiving CDK4/6 inhibitor–based therapy as the standard of care. Patients were enrolled in the prospective observational Roswell Park Ciclib Study (ClinicalTrials.gov identifier: NCT04526587 ). RESULTS In the metastatic setting, TKa levels in baseline samples were inversely associated with the duration of PFS (hazard ratio, 1.91, P = .03). There was also a reduction in TKa levels from baseline to on-treatment in metastatic disease that displayed longer PFS (≥20 months; 120.7 DiviTum units of activity, DuA v 30.6 DuA, P = .028). Individuals with metastatic disease that displayed shorter PFS (≤8 months) presented with higher TKa values on treatment (220.2 DuA v 30.6 DuA, P = .008) compared with patients with longer PFS. In early-stage high-risk cases, TKa values were lower on treatment compared with baseline (41.4 DuA v 114.8 DuA, P = 3.55e-08). CONCLUSION These findings support further investigation of circulating TKa levels as a continuous prognostic and predictive biomarker of response to CDK4/6 inhibitor–based therapy. Future studies are well-suited to assess definitive TKa cutoff values to inform treatment decisions.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
PURPOSE The PENELOPE-B trial (ClinicalTrials.gov identifier: NCT01864746 ) recruited patients with hormone receptor+/human epidermal growth factor receptor 2– early breast cancer without a pathological complete response after taxane-containing neoadjuvant chemotherapy and at a high risk of relapse. Patients were randomly assigned (1:1) to receive 13 cycles of palbociclib once daily or placebo on days 1-21 in a 28-day cycle in addition to endocrine therapy (ET). PENELOPE-B did not show improved invasive disease-free survival (iDFS) after adding palbociclib to ET. This retrospective analysis investigated the impact of germline pathogenic variant (PV) status of BRCA1/2 and non- BRCA1/2 cancer predisposition genes on the outcomes of PENELOPE-B trial patients. METHODS In total, 445 patients were sampled following a case-cohort design and 442 were analyzed for germline PVs. Statistical analyses were performed for time-to-event end points (iDFS, distant disease-free survival [DDFS], and overall survival [OS]). RESULTS Of the 442 patients, 42 carried PVs in any cancer predisposition gene; 15 carried BRCA1/2 PVs. Irrespective of the treatment arms, PV status was not a prognostic factor. Regarding the treatment arms in BRCA1/2 PV carriers, numerically better 3-year outcomes were observed in the palbociclib arm (iDFS, 95%; DDFS, 95%; OS, 100%) than in the placebo arm (iDFS, 72.8%; DDFS, 72.8%; OS, 87.5%; hazard ratios palbociclib v placebo 0.349 [iDFS] and 0.562 [DDFS], not calculated for OS, too few events). In patients without BRCA1/2 PVs, the differences in 3-year outcomes were negligible. PVs in non- BRCA1/2 cancer predisposition genes did not influence the efficacy of palbociclib, although gene-specific effects could not be excluded. CONCLUSION Patients with BRCA1/2 PVs had numerically better outcomes after palbociclib. However, the number of BRCA1/2 carriers was small. Larger randomized clinical trials should consider the PV status to further evaluate whether BRCA1/2 PV carriers benefit from cyclin-dependent kinase 4 and 6 inhibitor treatment.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (24)
Agnieszka Witkiewicz
Professor of Pathology and Oncology
Roswell Park Comprehensive Cancer Center
Sheila Stewart
Professor
Washington University in St. Louis
Pankaj Singh
Professor and Chair
University of Oklahoma Health Sciences Center
Michael Feigin
Assistant Professor
Roswell Park Comprehensive Cancer Center
Scott Powers
Professor
Stony Brook University
Alice Soragni
University of California
Mark Long
Assistant Professor of Oncology
Roswell Park Comprehensive Cancer Center
Katerina Gurova
Associate Professor
Roswell Park Comprehensive Cancer Center
David G. DeNardo
Professor of Medicine
Washington University School of Medicine
Karen McLean
Professor
Roswell Park Comprehensive Cancer Center
Seock-Ah Im
Professor
Seoul National University College of Medicine
Seth M. Rubin
University of California
Jeffrey Tyner
Professor
Oregon Health & Science University
Prasenjit Dey
Roswell Park Comprehensive Cancer Center
Ethan Abel
Associate Member/Associate Professor
Roswell Park Comprehensive Cancer Center
Karen A. Gelmon
The University of British Columbia
Sheheryar Kabraji
Associate Professor
Roswell Park Comprehensive Cancer Center
Deborah Novack
Professor
Washington University in St. Louis
Corinna Ernst
Hannover Medical School
Gregory Longmore
Professor
Washington University in St. Louis
Ioannis Sanidas
Principal Investigator
Massachusetts General Hospital
Miguel Martin
Universidad Complutense de Madrid
Xingxing Zang
Albert Einstein College of Medicine
Donghwa Kim
University of California, San Francisco
Make your next move.
Prepare your application
Review drafts before you send them.